Effect of lercanidipine on kidney microanatomy in Cohen-Rosenthal diabetic hypertensive rats

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 12, Issue 2, 2007, Pages 145-152

  Rosenthal, Talma ^a   Rosenmann, Eliezer ^b   Tomassoni, Daniele ^c   Amenta, Francesco ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Diabetic hypertensive rat; Kidney; Lercanidipine

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; LERCANIDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTERY DIAMETER; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; KIDNEY BLOOD VESSEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, EXPERIMENTAL; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; HYPERTENSION; KIDNEY; MALE; RATS; RENAL ARTERY; RENAL CIRCULATION;

EID: 34249678704     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248407300621     Document Type: Article

References (50)

1. El-Atat F., McFarlane SI, Sowers JR Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr Hypertens Rep. 2004 ; 6: 215-223.
2. Verdecchia P., Reboldi G., Angeli F., et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004 ; 43: 963-969.
3. Anavekar NS, Gans DJ, Berl T., et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl. 2004 ; 92: S50 - S55.
4. United States Renal Data System. USRDS. 1999 Annual Data Report. Bethesda. MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases ; 1999: 25-38.
5. Leon CA, Raij L. Interaction of haemodynamic and metabolic pathways in the genesis of diabetic nephropathy. J Hypertens. 2005 ; 23: 1931-1937.
6. United States Renal Data System. USRDS. 2000 Annual Data Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases ; 2001. Available at: http://www.usrds.org/adr_2000.htm. Accessed March 18, 2002.
7. European Dialysis and Transplant Association. Report on management of renal failure in Europe, XXVI, 1995. Nephrol Dial Transplant. 1996 ; 11 (suppl 7). 1-32.
8. Chen S., Yuan CM, Haddy FJ, Pamnani MB Effects of administration of insulin on streptozotocin induced diabetic hypertension rat. Hypertension. 1994 ; 23: 1046-1050.
9. Yamori Y., Ohtaka M., Ueshima H., et al. Glucose metabolism in spontaneously hypertensive rats. Jpn Heart J. 1978 19: 559-560.
10. Kasiske BL, O'Donnel MP, Keane WS Zucker rat model of obesity, insulin resistance, hyperinsulinemia and renal injury. Hypertension. 1992 ; 19: I-110-I - 115.
11. Cohen AM, Rosenmann E., Rosenthal T. The Cohen diabetic (non-insulin-dependent) hypertensive rat model. Description of the model and pathologic findings. Am J Hypertens. 1993 ; 6: 989-995.
12. Rosenmann E., Cohen AM The pathology of the Cohen diabetic rat. In: Cohen AM, Rosenmann E, eds. The Cohen Diabetic Rat. Basel, Switzerland: Karger ; 1990: 54-75.
13. Ritz E., Fliser D., Siebels M. Pathophysiology of hypertension renal damage. Am J Hypertens. 1993 ; 6: S241 - S244.
14. Krowlewski AS Predisposition to hypertension and susceptibility to renal disease in insulin diabetes mellitus. N Eng J Med. 1988 ; 318: 140-145.
15. Ritz E., Orth SR Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999 ; 341: 1127-1133.
16. Mogensen CE Drug treatment for hypertensive patients in special situation: diabetes and hypertension. Clin Exp Hyperten. 1999 ; 21: 895-906.
17. Angeli F., Verdecchia P., Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 12 studies with 103,793 subjects. Am J Hypertens. 2004 ; 17: 817-822.
18. Sabbatini M., Leonardi A., Testa R., et al. Effect of calcium antagonist on glomerular arterioles in spontaneously hypertensive rats. Hypertension. 2000 ; 35: 775-779.
19. Sabbatini M., Vitaioli L., Baldoni E., Amenta F. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2000 ; 294: 948-954.
20. Manjunath G., Tighioouart H., Ibrahim H., et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003 ; 41: 47-55.
21. Go AS, Chertow GM, Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 ; 351: 1296-1305.
22. Santoro D., Natali A., Palombo C., et al. Effect of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension. 1992 ; 20: 181-191.
23. Burnier M., Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens. 2006 ; 24: 11-25.
24. Lewis EJ, Hunsicker LG, Clarke WR,, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 ; 345: 851-860.
25. Arauz-Pacheco C., Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care. 2002 ; 25: 134-147.
26. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care. 2004 ; (suppl 1). S65 - S67.
27. Cooper ME, Tikellis C., Thomas MC Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system. J Hypertens Suppl. 2006 ; 24: S57 - S63.
28. Sevak AR, Goyal RK Effects of chronic treatment with lisinopril on cardiovascular complication in streptozotocin diabetic and DOCA hypertensive rats. Pharmacol Res. 1996 ; 34: 201-209.
29. Rosenthal T., Erlich Y., Rosenmann E., Cohen A. Effects of enalapril, losartan and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat. Hypertension. 1997 ; 29: 1260-1264.
30. Goyal RK, Satia MC, Bangaru RA, Gandhi TP Effect of long-term treatment with enalapril in streptozotocin diabetic and DOCA hypertensive rats. J Cardiovasc Pharmacol. 1998 ; 32: 317-322.
31. Murali B., Goyal RK Improvement in insulin sensitivity by losartan in non-insulin-dependent diabetic (NIDDM) rats. Pharmacol Res. 2001 ; 44: 385-389.
32. Sica DA Pharmacotherapy review: calcium channel blockers. J Clin Hypertens (Greenwich). 2006 ; 8: 53-56.
33. Messerli FH Calcium antagonists in hypertension: from hemodynamics to outcomes. Am J Hypertens. 2002 ; 15: 94S - 97S.
34. Giordano M., Sanders LR, Castellino P., Canessa ML, DeFronzo RA Effect of alpha-adrenergic blockers, ACE inhibitors and calcium channel antagonist on renal function in hypertensive non-insulin-dependent diabetic patients. Nephron. 1996 ; 72: 447-453.
35. Tuomilehto J., Rastenyte D., Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999 ; 340: 677-684.
36. Roca-Cusachs A., Triposkiadis F. Antihypertensive effect of manidipine. Drugs. 2005 ; 65 (suppl 2). 11-19.
37. Mason RP, Mak IT, Trumbore MW, Mason PE Antioxidant properties of calcium antagonists related to membrane biophysical interactions. Am J Cardiol. 1999 ; 84: 16L - 22L.
38. Ha H., Lee HB Oxidative stress in diabetic nephropathy: basic and clinical information. Curr Diab Rep. 2001 ; 1: 282-287.
39. Menne J., Park JK, Agrawai R., et al. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. FASEB J. 2006 ; 20: 994-996.
40. Dalla Vestra M, Pozza G., Mosca A., et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab. 2004 ; 17: 259-266.
41. Agrawal R., Marx A., Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens. 2006 ; 24: 185-192.
42. Volpe M., Savoia C., De Paolis P, et al. The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol. 2002 ; 13: 173-178.
43. Robles NR, Pastor L., Manjon M., et al. Lercanidipine in diabetic patients with renal failure [in Spanish]. Nefrologia. 2004 ; 24: 338-343.
44. Amenta F., Peleg E., Tomassoni D., Sabbatini M., Rosenthal T. Effect of treatment with lercanidipine on heart of Cohen-Rosenthal diabetic hypertensive rats. Hypertension. 2003 ; 41: 1350-1355.
45. Hayashi, K., Nagahama T., Oka K., Epstein M., Saruta T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res. 1996 ; 19: 31-36.
46. Loutzenhiser R., Epstein M., Hayashi K. Renal hemodynamic effects of calcium antagonists. Am J Cardiol. 1989 ; 64: 41F - 45F.
47. Saruta T., Kanno Y., Hayashi K., Konishi K. Antihypertensive agents and renal protection: Calcium channel blockers. Kidney Int Suppl. 1996 ; 55: S52 - S56.
48. Arima S., Ito S., Omata K., Tsunoda K., Yaoita H., Abe K. Diverse effects of calcium antagonists on glomerular hemodynamics. Kidney Int. 1996 ; 49 (suppl 55). S132 - S134.
49. Kimura K., Suzuki N., Mise N., et al. Effects of barnidipine hydrochloride, a calcium channel blocker, on renal microcirculation in rats: a pilot study. Curr Ther Res. 1998 ; 59: 826-834.
50. Yamamoto T., Tomura Y., Tanaka H., Kajiya F. In vivo visualization of characteristics of renal microcirculation in hypertensive and diabetic rats. Am J Physiol Renal Physiol. 2001 ; 281: F571 - F577.